Logo

Janssen Reports New Analysis of Xarelto (rivaroxaban) + Aspirin from the P-III (VOYAGER PAD) Trial for PAD and Co-Morbid Conditions

Share this

Janssen Reports New Analysis of Xarelto (rivaroxaban) + Aspirin from the P-III (VOYAGER PAD) Trial for PAD and Co-Morbid Conditions

Shots:

  • The P-III (VOYAGER PAD) trial evaluates Xarelto (2.5mg, bid) + aspirin (100mg, qd) vs aspirin alone in a ratio (1:1) in 6564 patients with PAD with/out CKD & with/out the history of statin therapy
  • The results showed a reduction in thrombotic hospitalizations due to thrombotic events (8.7% vs 12.1%) for PAD patients with/out CKD, 4.7% ARR in the subgroup with CKD (7.9% vs 12.6%)
  • The analysis showed that patients who received Xarelto + aspirin in addition to statin therapy had a 19% reduction in 1EPs composite of ALI, 26% of MALE & 32% in acute limb injury & reduced the composite of MACE or MALE after revascularization for PAD. Both analyses showed a numerical increase in TIMI major bleeding

Ref: Janssen | Image: Janssen

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions